Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 12, 2009, Pages 1471-1476

  Ulukaya, Engin ^a   Yilmaz, Yusuf ^b   Moshkovskii, Sergei ^c   Karpova, Maria ^c   Pyatnitskiy, Mikhail ^c   Atug, Ozlen ^b   Dolar, Enver ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Matrix assisted laser desorption ionization time of flight mass spectrometry; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Proteomics; Serum

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; BODY MASS INDEX; CASE-CONTROL STUDIES; FATTY LIVER; FATTY LIVER, ALCOHOLIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 72449172087     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903353379     Document Type: Article

References (21)

1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009;49:306-17.
2. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43: 509-18.
3. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep. 2008;10:73-80.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
5. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008;28:386-95.
6. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-98.
7. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582-9.
8. Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-25.
9. Conrotto P, Souchelnytskyi S. Proteomic approaches in biological and medical sciences: principles and applications. Exp Oncol. 2008;30:171-80.
10. Matt P, Fu Z, Fu Q, Van Eyk JE. Biomarker discovery: proteome fractionation and separation in biological samples. Physiol Genomics. 2008;33:12-7.
11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.
12. Gyuon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Mach Learn. 2002;46:389-422.
13. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:833-9.
14. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 2009;16:418-29.
15. Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, Partin AW, et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009;181:1407-14.
16. Yuditskaya S, Tumblin A, Hoehn GT, Wang G, Drake SK, Xu X, et al. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood. 2009;113:1122-8.
17. Bennett MR, Ravipati N, Ross G, Nguyen MT, Hirsch R, Beekman RH, et al. Using proteomics to identify preprocedural risk factors for contrast induced nephropathy. Proteomics Clin Appl. 2008;2:1058-64.
18. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005;42:665-74. (Pubitemid 41233660)
19. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH, et al. Serum proteomic profiling of obese patients: correlation with pathology and evolution after bariatric. surgery Gut. 2009;58: 825-32.
20. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem. 2006;52:1223-37.
21. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. 2005;11:1110-8.